Sarcoma News and Research

RSS

Study finds link between tumor microbiome and immune system in sarcoma patients

In a significant new study, UC Davis Comprehensive Cancer Center researchers have uncovered a link between a patient's microbiome and their immune system that can potentially be used to improve the treatment of soft tissue sarcoma.

30 Jan 2023

New drug target for Ewing sarcoma discovered

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a new drug target for Ewing sarcoma, a rare kind of cancer usually diagnosed in children and young adults.

20 Jan 2023

Study generates a comprehensive genetic map to identify important genes that cause sarcoma

Several genes that cause sarcoma have been identified in the first comprehensive genetic map of sarcomas, generated by research led by Omico, the Garvan Institute of Medical Research and UNSW Sydney.

19 Jan 2023

Heritable pathogenic defects in genes may increase the risk for sarcomas

Heritable pathogenic defects in genes related to mitosis and telomere function may specifically increase the risk for sarcomas – rare cancers that develop in muscles, bones, and other connective tissues, researchers report.

19 Jan 2023

Study uncovers a new role for Slit2 signaling in stimulating Ewing sarcoma growth

A new research paper was published in Genes & Cancer on December 14, 2022, entitled, "Slit2 signaling stimulates Ewing sarcoma growth."

13 Jan 2023

Novel T cell receptor therapy shows early promise for treating solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

9 Jan 2023

Vitamin D can help the immune system fight tuberculosis, study says

Most people probably associate tuberculosis with a leaky loft in 20th-century Paris. But as a matter of fact, tuberculosis is not ancient history.

6 Jan 2023

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS).

28 Dec 2022

Collaborative work unravels hidden molecular secrets of age-related diseases

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced today the release of the first batch of results from the collaborative work directed to perform multi-omics-based analyses in the context of age-related diseases using an AI-driven target and drug discovery pipeline.

2 Dec 2022

NYU Langone’s Center for Amputation Reconstruction now adds osseointegration treatment to its other surgical techniques

NYU Langone Health has completed its first set of surgeries using the only U.S. Food and Drug Administration (FDA)-approved implantable prosthetic for people with limb loss available in the greater New York City area.

1 Dec 2022

Unique clinical trial in pet dogs could unlock treatment breakthrough for childhood cancers

Telethon Kids Institute is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.

14 Nov 2022

Researchers highlight a significant cancer disparity among young Black men in the American South

Research shows that incidences of Kaposi's sarcoma among people living with HIV have fallen significantly over the past two decades, but a new evaluation of data led by researchers at UTHealth Houston highlights a significant disparity among one particular demographic – young Black men in the American South.

10 Nov 2022

$Hypofractionated radiotherapy for patients with soft tissue sarcomas can be a safe, effective alternative to standard of care$

Hypofractionated radiotherapy for patients with soft tissue sarcomas can be a safe, effective alternative to standard of care

Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.

6 Nov 2022

Bioinformatics analysis of monkeypox virus-host cell interactions

A recent study posted to the bioRxiv* preprint server reported the interaction between monkeypox and human cells. Molecular sequences were screened to identify differentially expressed genes (DEGs) and their associated signal pathway, expression regulation, and metabolic pathways.

18 Oct 2022

Scientists develop an unprecedented animal model to investigate Ewing sarcoma

Ewing sarcoma is the second most frequent bone tumour in children, adolescents, and young adults. There is no specific treatment for this disease and current management is still limited to surgery, radiotherapy, and chemotherapy.

7 Oct 2022

Monkeypox virus infection in an immunocompromised patient

Researchers assessed the manifestations of the monkeypox infection in an immunocompromised patient.

19 Sep 2022

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.

13 Sep 2022

Study uncovers how air pollution can trigger lung cancer in individuals with no history of smoking

A new study revealed a link between air pollution and lung cancer in non-smokers.

13 Sep 2022

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

13 Sep 2022

Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors

12 Sep 2022

Sarcoma News and Research

Study finds link between tumor microbiome and immune system in sarcoma patients

New drug target for Ewing sarcoma discovered

Study generates a comprehensive genetic map to identify important genes that cause sarcoma

Heritable pathogenic defects in genes may increase the risk for sarcomas

Study uncovers a new role for Slit2 signaling in stimulating Ewing sarcoma growth

Novel T cell receptor therapy shows early promise for treating solid tumors

Vitamin D can help the immune system fight tuberculosis, study says

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

Collaborative work unravels hidden molecular secrets of age-related diseases

NYU Langone’s Center for Amputation Reconstruction now adds osseointegration treatment to its other surgical techniques

Unique clinical trial in pet dogs could unlock treatment breakthrough for childhood cancers

Researchers highlight a significant cancer disparity among young Black men in the American South

Hypofractionated radiotherapy for patients with soft tissue sarcomas can be a safe, effective alternative to standard of care

Bioinformatics analysis of monkeypox virus-host cell interactions

Scientists develop an unprecedented animal model to investigate Ewing sarcoma

Monkeypox virus infection in an immunocompromised patient

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Study uncovers how air pollution can trigger lung cancer in individuals with no history of smoking

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News